177 related articles for article (PubMed ID: 35406609)
21. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized
Hundshammer C; Braeuer M; Müller CA; Hansen AE; Schillmaier M; Düwel S; Feuerecker B; Glaser SJ; Haase A; Weichert W; Steiger K; Cabello J; Schilling F; Hövener JB; Kjær A; Nekolla SG; Schwaiger M
Theranostics; 2018; 8(17):4765-4780. PubMed ID: 30279736
[TBL] [Abstract][Full Text] [Related]
23. Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting.
Virostko J; Sorace AG; Slavkova KP; Kazerouni AS; Jarrett AM; DiCarlo JC; Woodard S; Avery S; Goodgame B; Patt D; Yankeelov TE
Breast Cancer Res; 2021 Nov; 23(1):110. PubMed ID: 34838096
[TBL] [Abstract][Full Text] [Related]
24. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.
Braman N; Prasanna P; Whitney J; Singh S; Beig N; Etesami M; Bates DDB; Gallagher K; Bloch BN; Vulchi M; Turk P; Bera K; Abraham J; Sikov WM; Somlo G; Harris LN; Gilmore H; Plecha D; Varadan V; Madabhushi A
JAMA Netw Open; 2019 Apr; 2(4):e192561. PubMed ID: 31002322
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Treatment Response With Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI in Patients With Early-Stage Breast Cancer Treated With Single-Dose Preoperative Radiotherapy: Initial Results.
Wang C; Horton JK; Yin FF; Chang Z
Technol Cancer Res Treat; 2016 Oct; 15(5):651-60. PubMed ID: 26134438
[TBL] [Abstract][Full Text] [Related]
26. Diffusion-Weighted MRI Is Insensitive to Changes in the Tumor Microenvironment Induced by Antiangiogenic Therapy.
Hauge A; Wegner CS; Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
Transl Oncol; 2018 Oct; 11(5):1128-1136. PubMed ID: 30036782
[TBL] [Abstract][Full Text] [Related]
27. Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging.
Consolino L; Longo DL; Dastrù W; Cutrin JC; Dettori D; Lanzardo S; Oliviero S; Cavallo F; Aime S
Int J Cancer; 2016 Jul; 139(2):404-13. PubMed ID: 26941084
[TBL] [Abstract][Full Text] [Related]
28. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
29. Dynamic Contrast-Enhanced MRI Evaluation of Pathologic Complete Response in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After HER2-Targeted Therapy.
Heacock L; Lewin A; Ayoola A; Moccaldi M; Babb JS; Kim SG; Moy L
Acad Radiol; 2020 May; 27(5):e87-e93. PubMed ID: 31444111
[TBL] [Abstract][Full Text] [Related]
30. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
31. Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts.
Whisenant JG; Sorace AG; McIntyre JO; Kang H; Sánchez V; Loveless ME; Yankeelov TE
Transl Oncol; 2014 Dec; 7(6):768-79. PubMed ID: 25500087
[TBL] [Abstract][Full Text] [Related]
32. Perfusion Parameters in Dynamic Contrast-enhanced MRI and Apparent Diffusion Coefficient Value in Diffusion-weighted MRI:: Association with Prognostic Factors in Breast Cancer.
Lee HS; Kim SH; Kang BJ; Baek JE; Song BJ
Acad Radiol; 2016 Apr; 23(4):446-56. PubMed ID: 26852247
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Two Mathematical Models of Cellularity Calculation.
Meyer HJ; Garnov N; Surov A
Transl Oncol; 2018 Apr; 11(2):307-310. PubMed ID: 29413764
[TBL] [Abstract][Full Text] [Related]
34. Anti-HER2 CD4
De La Cruz LM; McDonald ES; Mick R; Datta J; Nocera NF; Xu S; Fisher CS; Czerniecki BJ
Ann Surg Oncol; 2017 Apr; 24(4):1057-1063. PubMed ID: 27826664
[TBL] [Abstract][Full Text] [Related]
35. Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen-receptor-positive breast cancer.
Shin HJ; Kim SH; Lee HJ; Gong G; Baek S; Chae EY; Choi WJ; Cha JH; Kim HH
NMR Biomed; 2016 Aug; 29(8):1070-8. PubMed ID: 27332719
[TBL] [Abstract][Full Text] [Related]
36. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI.
Liang J; Dai W; Li Z; Liang X; Xiao M; Xie C; Li X
BMC Cancer; 2022 Oct; 22(1):1033. PubMed ID: 36192709
[TBL] [Abstract][Full Text] [Related]
38. Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?
Kim JY; Kim SH; Kim YJ; Kang BJ; An YY; Lee AW; Song BJ; Park YS; Lee HB
Magn Reson Imaging; 2015 Jan; 33(1):72-80. PubMed ID: 25179138
[TBL] [Abstract][Full Text] [Related]
39. Multimodal image-guided surgery of HER2-positive breast cancer using [
Deken MM; Bos DL; Tummers WSFJ; March TL; van de Velde CJH; Rijpkema M; Vahrmeijer AL
EJNMMI Res; 2019 Nov; 9(1):98. PubMed ID: 31754913
[TBL] [Abstract][Full Text] [Related]
40. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
